GENOTYPE-PHENOTYPE ASSOCIATIONS PROVIDE A RATIONAL TO IDENTIFY POTENTIALLY ACTIONABLE VUS

Silvana Lobo  ¹     Rita Monteiro     Liliana Sousa     Hugo Pinheiro     Sergio Castedo     Fatima Carneiro  ²     Luzia Garrido  ³     Manuel Teixeira  ⁴     Genevieve Michils  ⁵     Vicent Bours  ⁶     Robin de Putter  ⁷     Lisa Golmard  ⁸     Chrystelle Colas     Maud Blanluet     Camille Desseignés  ⁹     Coulet Florence     Stefan Aretz  ¹⁰     Isabel Spier  ¹¹     Robert Hüneburg     Guglielmina Ranzani  ¹²     Maurizio Genuardi  ¹³     Ana Patiño-García  ¹⁴     Conxi Lázaro  ¹⁵     Gabriel Capellà     Joan Brunet-Vidal  ¹⁶     Judith Balmana  ¹⁷     Elena Domínguez-Garrido  ¹⁸     Marjolin Ligtenberg  ¹⁹     Rebecca FitzGerald  ²⁰     Emma Woodward  ²¹     Gareth Evans  ²²     Helen Hanson  ²³     Conceição Egas  ²⁴     M. Isabel Tejada et al.  ²⁵     Nicoline Hoogerbrugge     Marc Tischkowitz  ²⁶     Carla Oliveira  ²⁷     José García Peláez     Patrick R. Benusiglio     Laura Gieldon & Evelyn Schrock  ²⁸     Elke Holinski-Feder & Verena Steinke  ²⁹     Daniele Calistri & Gianluca Tedaldi  ³⁰     Catarina Silveira & Inês Silva  ³¹     Mateja Krajc, Ana Blatnik & Srdjan Novacovik  ³²     Jose Soto  ³³     Kristina Lagerstedt-Robinson & Svetlana Bajali Lagercrantz  ³⁴     Karim Dahan & Damien Feret  ^35    
1 i3s, Porto, Portugal
² IPATIMUP, Porto/PT, Porto, Portugal
³ Centro Hospitalar Universitário São João (CHUSJ), Porto, Portugal
⁴ IPO, Instituto Português de Oncologia do Porto, Porto, Portugal
⁵ University of Leuven, Leuven, Belgium
⁶ Laboratory of Human Genetics, GIGA-Institute, Liège, Belgium
⁷ University Hospital of Ghent, Ghent, Belgium
⁸ Institut Curie, Paris, France
⁹ GH Pitié- Salpêtrière, Paris, France
¹⁰ University Hospital Bonn, Bonn, Germany
¹¹ University of Bonn, Bonn, Germany
¹² University of Pavia, Pavia, Italy
¹³ Institute of Genomic Medicine, Catholic University of the Sacred Heart, Rome, Italy
¹⁴ University Clinic of Navarra, Pamplona, Spain
¹⁵ Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Barcelona, Spain
¹⁶ Hereditary Cancer Programme, Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL) and Biomedical Research Institute (IDIBGI), Barcelona-Girona, Spain
¹⁷ Hospital Vall d’Hebron and Universitat Autonoma de Barcelona, Barcelona, Spain
¹⁸ Molecular Diagnostics Laboratory, Fundación Rioja Salud, Logroño, Spain
¹⁹ Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands
²⁰ MRC Cancer Unit, Hutchison-MRC Research Centre, Cambridge, United Kingdom
²¹ University of Manchester, Manchester, United Kingdom
²² Manchester Centre for Genomic Medicine, Manchester, United Kingdom
²³ St Georges NHS Foundation Trust, London, United Kingdom
²⁴ Biocant- Transfer Technology Association, Cantanhede, Portugal
²⁵ Biocruces Health Research Institute, Barakaldo, Spain
²⁶ University of Cambridge, Cambridge, United Kingdom
²⁷ Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal
²⁸ TU Dresden, Medical Faculty CGC, Dresden, Germany
²⁹ Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
³⁰ Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
³¹ Genomed Diagnósticos de Medicina Molecular, S.A., Lisbon, Portugal
³² Institute of Oncology Ljubljana, Ljubljana, Slovenia
³³ Elche University Hospital, Elche, Spain
³⁴ Karolinska Institutet, Stockholm, Sweden
³⁵ Institut de Pathologie et de Génétique, Gosselies, Belgium

Topic
Digestive Oncology, Disease Mechanisms, Histopathology

Session
Gastric cancer spreading: What are the risks?

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)